All Stories

  1. Availability of drug susceptibility testing to new/re-purposed anti-tuberculosis drugs: a TBnet study

    Article • September 2021, European Respiratory Society (ERS)

    Lorenzo Guglielmetti

  2. WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion?

    Article • European Respiratory Journal, March 2020, European Respiratory Society (ERS)

    Lorenzo Guglielmetti

  3. QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study

    Article • European Respiratory Journal, June 2018, European Respiratory Society (ERS)

    Lorenzo Guglielmetti

  4. Safety and efficacy of exposure to bedaquiline−delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia

    Article • European Respiratory Journal, February 2018, European Respiratory Society (ERS)

    Lorenzo Guglielmetti, Professor JEROME ROBERT

  5. Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance

    Article • European Respiratory Journal, July 2017, European Respiratory Society (ERS)

    Lorenzo Guglielmetti

  6. Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity?

    Article • European Respiratory Journal, May 2017, European Respiratory Society (ERS)

    Lorenzo Guglielmetti

  7. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis

    Article • European Respiratory Journal, December 2016, European Respiratory Society (ERS)

    Lorenzo Guglielmetti, Professor JEROME ROBERT